File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Genomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse

TitleGenomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse
Authors
KeywordsClinically relevant genomic alteration
nasopharyngeal carcinoma
next-generation sequencing
prognostic biomarker
relapse
Issue Date2020
PublisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/iero20#.VgGYxUaFOnI
Citation
Expert Review of Molecular Diagnostics, 2020, v. 20 n. 11, p. 1149-1159 How to Cite?
AbstractBackground: Although the majority of nasopharyngeal carcinoma (NPC) patients demonstrate favorable outcomes after radiotherapy and/or chemotherapy, about 8–10% of patients will develop recurrent disease, and genomic alterations (GAs) associated with the recurrence are unclear. Methods: This study investigated the GAs in the paired primary tumors and recurrent tumors of 7 NPC patients with relapse, as well as the primary tumors of 15 NPC patients without relapse by deep targeted next-generation sequencing on 440 cancer-related genes. Results: BRCA1 and TP53 mutations were significantly enriched in patients with relapse (P = 0.021 and P = 0.023, respectively). Survival analysis revealed that the GAs of TP53, ZNF217, VEGFB, CDKN1B, GNAS, PRDM1, and MEN1 were associated with significantly shorter overall survival. The GAs of the tumor also altered after treatment in the relapsed group, and five genes (CDK4, FGFR3, ALK, BRCA1, and CHEK2) in the recurrent tumors were potentially druggable. Conclusions: The discovery of GAs associated with recurrence or survival in NPC may serve as potential prognostic gene signatures of high-risk patients. Targeted therapies are available in some of the clinically relevant GAs and may be considered in future clinical trials. Given the limitation of the sample size, validation by a larger cohort is warranted.
Persistent Identifierhttp://hdl.handle.net/10722/293331
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 0.823
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCho, WCS-
dc.contributor.authorTse, KP-
dc.contributor.authorNgan, RKC-
dc.contributor.authorCheuk, W-
dc.contributor.authorMa, VWS-
dc.contributor.authorTang, YT-
dc.contributor.authorYip, TTC-
dc.contributor.authorTan, KT-
dc.contributor.authorChen, SJ-
dc.date.accessioned2020-11-23T08:15:13Z-
dc.date.available2020-11-23T08:15:13Z-
dc.date.issued2020-
dc.identifier.citationExpert Review of Molecular Diagnostics, 2020, v. 20 n. 11, p. 1149-1159-
dc.identifier.issn1473-7159-
dc.identifier.urihttp://hdl.handle.net/10722/293331-
dc.description.abstractBackground: Although the majority of nasopharyngeal carcinoma (NPC) patients demonstrate favorable outcomes after radiotherapy and/or chemotherapy, about 8–10% of patients will develop recurrent disease, and genomic alterations (GAs) associated with the recurrence are unclear. Methods: This study investigated the GAs in the paired primary tumors and recurrent tumors of 7 NPC patients with relapse, as well as the primary tumors of 15 NPC patients without relapse by deep targeted next-generation sequencing on 440 cancer-related genes. Results: BRCA1 and TP53 mutations were significantly enriched in patients with relapse (P = 0.021 and P = 0.023, respectively). Survival analysis revealed that the GAs of TP53, ZNF217, VEGFB, CDKN1B, GNAS, PRDM1, and MEN1 were associated with significantly shorter overall survival. The GAs of the tumor also altered after treatment in the relapsed group, and five genes (CDK4, FGFR3, ALK, BRCA1, and CHEK2) in the recurrent tumors were potentially druggable. Conclusions: The discovery of GAs associated with recurrence or survival in NPC may serve as potential prognostic gene signatures of high-risk patients. Targeted therapies are available in some of the clinically relevant GAs and may be considered in future clinical trials. Given the limitation of the sample size, validation by a larger cohort is warranted.-
dc.languageeng-
dc.publisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/iero20#.VgGYxUaFOnI-
dc.relation.ispartofExpert Review of Molecular Diagnostics-
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectClinically relevant genomic alteration-
dc.subjectnasopharyngeal carcinoma-
dc.subjectnext-generation sequencing-
dc.subjectprognostic biomarker-
dc.subjectrelapse-
dc.titleGenomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse-
dc.typeArticle-
dc.identifier.emailNgan, RKC: rkcngan@hku.hk-
dc.identifier.authorityNgan, RKC=rp02371-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/14737159.2020.1835473-
dc.identifier.pmid33040630-
dc.identifier.scopuseid_2-s2.0-85095771250-
dc.identifier.hkuros319705-
dc.identifier.volume20-
dc.identifier.issue11-
dc.identifier.spage1149-
dc.identifier.epage1159-
dc.identifier.isiWOS:000586926400001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats